Prescription drug · BLA
Poteligeo (mogamulizumab-kpkc) NDC 42747-761
Mogamulizumab 4 mg/mL · Injection · Intravenous · Kyowa Kirin, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 42747-761-01 | 42747076101 | 1 VIAL, GLASS in 1 CARTON (42747-761-01) / 5 mL in 1 VIAL, GLASSMarketed from Aug 8, 2018 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Poteligeo
- Generic name (nonproprietary)
- mogamulizumab-kpkc
- Active ingredients
- Mogamulizumab — 4 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Kyowa Kirin, Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761051
- Marketing start
- Listing expires
- Other FDA classes
- Monoclonal (Chemical structure)Chemokine Receptor Type 4 Interactions (Mechanism)
- Identifiers
- Product ID 42747-761_2002b8eb-c6a6-4f3f-8a58-963fe6c015c4SPL ID 2002b8eb-c6a6-4f3f-8a58-963fe6c015c4SPL set ID e53960ab-42a1-40d1-9c7d-eb013fe7f18fRxCUI 2054081, 2054086UNII YI437801BE
- Pharmacologic class
- Chemokine Receptor Type 4 Interaction; Monoclonal Antibody
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N442747076101followed by a unit qualifier and the quantityPackage 42747-0761-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 ).
Excerpt only. Read the full label for complete information.